|

LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

RECRUITINGSponsored by Karl Landsteiner Institute for Lung Research and Pneumological Oncology
Actively Recruiting
SponsorKarl Landsteiner Institute for Lung Research and Pneumological Oncology
Started2020-04-17
Est. completion2030-04
Eligibility
Age18 Years – 125 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04733430

Summary

This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.

Eligibility

Age: 18 Years – 125 YearsHealthy volunteers accepted
Inclusion Criteria:

* Informed consent
* Histologically confirmed lung cancer
* Age ≥ 18 years
* Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments

Exclusion Criteria:

\-

Conditions2

CancerLung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.